Hansa Biopharma AB (publ)
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Hansa Biopharma AB (publ) generated cash of -$755,654,000, which is less than the previous year. Cash used in financing activities reached the amount of -$7,545,000 last year. Net change in cash is therefore -$764,119,000.
Cash Flow
| 2014 | -23.62M | -1.31M | 35.00M |
|---|---|---|---|
| 2015 | -57.79M | -2.79M | 226.12M |
| 2016 | -94.56M | -45.41M | 177.88M |
| 2017 | -150.10M | 2.69M | 514.90M |
| 2018 | -204.56M | -387.47M | 450.30M |
| 2019 | -334.77M | 85.78M | -8.88M |
| 2020 | -290.27M | 182.53M | 1.06B |
| 2021 | -481.16M | -2.39M | -4.85M |
| 2022 | -502.73M | 229.31M | 1.11B |
| 2023 | -755.65M | -284K | -7.54M |
0RC7.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.49B | 651.34M | 1.13B | 181.69M | 439.44M | 581.07M | 213.58M | 175.68M | 10.15M | 90K |
Operating activities | ||||||||||
Net income | -831.72M | -611.13M | -548.28M | -422.80M | -359.66M | -246.49M | -176.08M | -111.13M | -66.20M | -24.70M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 19.79M | 12.05M | 8.60M | 7.66M | 7.46M | 1.83M | 3.77M | 3.44M | 989K | 1.34M |
Stock-based compensation expense | 0 | 58.22M | 56.62M | 43.34M | 7.24M | 0 | 190K | 343K | 199K | 0 |
| Deferred income tax benefit | 0 | 58.22M | 56.62M | 43.34M | 7.24M | 0 | 190K | 343K | 199K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -35.06M | -33.24M | -39.35M | -1.30M | -6.62M | 0 | -4.26M | 0 | -566K | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 24.48M | 9.11M | 28.57M | -23.89M | 10.14M | 0 | -2.71M | 0 | 0 | 0 |
Cash generated by operating activities | -755.65M | -502.73M | -481.16M | -290.27M | -334.77M | -204.56M | -150.10M | -94.56M | -57.79M | -23.62M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | -87K | -493.98M | -240.89M | -197.50M | -1.47M | -115K |
Investments In Property Plant And Equipment | -284K | -3.33M | -2.39M | -294K | -3.42M | -2.49M | -2.40M | -984K | -1.31M | -1.20M |
Acquisitions Net | 0 | 0 | 0 | 0 | 87K | 127K | 0 | -1.92M | 0 | 0 |
Cash generated by investing activities | -284K | 229.31M | -2.39M | 182.53M | 85.78M | -387.47M | 2.69M | -45.41M | -2.79M | -1.31M |
Financing activities | ||||||||||
Common Stock Issued | 0 | 396.19M | 0 | 1.07B | 3.18M | 471.06M | 545.40M | 185.42M | 248.16M | 37.04M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -401K | 0 | 0 | 0 |
Repayments of term debt | 0 | 728.37M | -4.85M | -4.67M | 0 | 0 | 0 | 0 | 0 | -519K |
Cash used in financing activities | -7.54M | 1.11B | -4.85M | 1.06B | -8.88M | 450.30M | 514.90M | 177.88M | 226.12M | 35.00M |
Net Change In Cash | -764.11M | 844.83M | -488.02M | 957.66M | -257.74M | -141.63M | 367.49M | 37.90M | 165.53M | 10.06M |
Cash at end of period | 732.06M | 1.49B | 651.34M | 1.13B | 181.69M | 439.44M | 581.07M | 213.58M | 175.68M | 10.15M |